Published 2 months ago • loading... • Updated 2 months ago

The U.S. approved an Alzheimer's drug. Seven patients subsequently died

Summary by National Post

Three others also suffered lasting disabilities, according to FDA reports obtained by a Freedom of Information Act request

7 Articles

All

Left

Center

Right

National Post

Lean Right

The U.S. approved an Alzheimer's drug. Seven patients subsequently died

Three others also suffered lasting disabilities, according to FDA reports obtained by a Freedom of Information Act request

2 months ago·Canada

Read Full Article

Bloomberg

Lean Left

The US Approved an Alzheimer's Drug. Seven Patients Subsequently Died

Despite the known risks of patients experiencing life-threatening side effects, prescribing standards vary widely among medical centers.

2 months ago·United States

Read Full Article

Pharmaphorum

Center

Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla

The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.

2 months ago

Read Full Article

merkur.de

Center

Too risky: EU authority stops Alzheimer's drug – expert responds "surprised"

The EU Commission has the last word, but the EMA's assessment is central: a new Alzheimer's drug does not make it into the EU.

2 months ago

Read Full Article

Die Presse

Lean Right

Furthermore, no new Alzheimer's drug in Austria

The European Medicines Agency (EMA) did not approve the active substance donanemab, but the risks for side effects such as brain swelling and brain bleeding were too high. In the USA, Japan, China and the UK, however, it was approved.

2 months ago·Vienna, Austria

Read Full Article

alzheimer-europe.org

Alzheimer Europe | The European Commission refers lecanemab decision to Appeal Committee

On 1 April, Eisai and Biogen announced that the European Commission has decided to refer the marketing authorisation approval decision of lecanemab in the EU to the Appeal Commi

2 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year